Improving shared decision making for lung cancer treatment by developing and validating an open-source web based patient decision aid for stage I-II non-small cell lung cancer

被引:0
|
作者
Halilaj, Iva [1 ,2 ]
Ankolekar, Anshu [1 ]
Lenaers, Anouk [1 ]
Chatterjee, Avishek [1 ]
Oberije, Cary J. G. [3 ]
Eppings, Lisanne [1 ]
Smit, Hans J. M. [4 ]
Hendriks, Lizza E. L. [5 ]
Jochems, Arthur [1 ]
Lieverse, Relinde I. Y. [1 ,6 ]
van Timmeren, Janita E. [7 ]
Wind, Anke [1 ]
Lambin, Philippe [1 ]
机构
[1] Maastricht Univ, GROW Sch Oncol, Dept Precis Med, D Lab, Maastricht, Netherlands
[2] Hlth Innovat Ventures, Maastricht, Netherlands
[3] Kheiron Med Technol, London, England
[4] Rijnstate Hosp, Arnhem, Netherlands
[5] Maastricht Univ, GROW Sch Oncol & Reprod, Dept Pulm Dis, Med Ctr, Maastricht, Netherlands
[6] Catharina Hosp, Dept Internal Med, Eindhoven, Netherlands
[7] Radboud Univ Nijmegen, Dept Radiat Oncol, Med Ctr, Nijmegen, Netherlands
来源
FRONTIERS IN DIGITAL HEALTH | 2024年 / 5卷
关键词
shared decision-making; open-source iPDA; participative medicine; NSCLC; patient decision aid; QUESTIONNAIRE; RADIOTHERAPY;
D O I
10.3389/fdgth.2023.1303261
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The aim of this study was to develop and evaluate a proof-of-concept open-source individualized Patient Decision Aid (iPDA) with a group of patients, physicians, and computer scientists. The iPDA was developed based on the International Patient Decision Aid Standards (IPDAS). A previously published questionnaire was adapted and used to test the user-friendliness and content of the iPDA. The questionnaire contained 40 multiple-choice questions, and answers were given on a 5-point Likert Scale (1-5) ranging from "strongly disagree" to "strongly agree." In addition to the questionnaire, semi-structured interviews were conducted with patients. We performed a descriptive analysis of the responses. The iPDA was evaluated by 28 computer scientists, 21 physicians, and 13 patients. The results demonstrate that the iPDA was found valuable by 92% (patients), 96% (computer scientists), and 86% (physicians), while the treatment information was judged useful by 92%, 96%, and 95%, respectively. Additionally, the tool was thought to be motivating for patients to actively engage in their treatment by 92%, 93%, and 91% of the above respondents groups. More multimedia components and less text were suggested by the respondents as ways to improve the tool and user interface. In conclusion, we successfully developed and tested an iPDA for patients with stage I-II Non-Small Cell Lung Cancer (NSCLC).
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Treatment of stage II non-small cell lung cancer
    Scott, WJ
    Howington, J
    Movsas, B
    CHEST, 2003, 123 (01) : 188S - 201S
  • [22] Development of a Shared Decision-Making Tool for Adjuvant Treatment for Patients with Resected Non-Small Cell Lung Cancer
    Jacome, C. Soto
    Hargraves, I.
    Ashara, Y.
    Perneth, S. Algarin
    Sivly, A.
    Gravholt, D.
    Sagen, C.
    Brito, J.
    Montori, V.
    Leventakos, K.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S510 - S511
  • [23] Safety and effectiveness of localized lung resection combined with neoadjuvant chemotherapy in the treatment of stage I-II non-small cell lung cancer
    Zhu, Bing
    Yang, Jianru
    Zhang, Pei
    Shen, Lin
    Li, Xiaolong
    Li, Jing
    ONCOLOGY LETTERS, 2017, 13 (04) : 2344 - 2348
  • [24] Therapy for stage I and stage II non-small cell lung cancer
    Tanoue, LT
    Ponn, RB
    CLINICS IN CHEST MEDICINE, 2002, 23 (01) : 173 - +
  • [25] Resection in Stage I/II Non-Small Cell Lung Cancer
    Smolle-Juettner, F. M.
    Maier, A.
    Lindenmann, J.
    Matzi, V.
    Neuboeck, N.
    CONTROVERSIES IN TREATMENT OF LUNG CANCER, 2010, 42 : 71 - 77
  • [26] Ablation of Stage I-II Non-Small Cell Lung Cancer in Patients With Interstitial Lung Disease: A Multicenter Retrospective Study
    Fintelmann, Florian J.
    Graur, Alexander
    Oueidat, Karim
    Simon, Judit
    Barnes, Jeanna M. Harvey
    McDermott, Shaunagh
    Genshaft, Scott J.
    Healey, Terrance T.
    Suh, Robert D.
    Maxwell, Aaron W. P.
    Abtin, Fereidoun
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2024, 222 (02)
  • [27] Shared decision making in the treatment of stage I non small cell lung cancer-a choice which should equally involve both sides
    Ottlakan, Aurel
    Furak, Jozsef
    Rocco, Gaetano
    ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (17)
  • [28] Are Insurance Companies Driving the Decision-Making Process for Stage I Non-Small Cell Lung Cancer (NSCLC) Patients?
    Arsenault, D. M.
    Lally, B. E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S513 - S514
  • [29] Validating margin status in lung wedge resection for clinical stage I non-small cell lung cancer
    Sawabata, Noriyoshi
    Kawase, Akikazu
    Takahashi, Nobumasa
    Kawaguchi, Takeshi
    Woo, Tetsukan
    Saito, Yuichi
    Shiono, Satoshi
    Matsutani, Noriyuki
    SURGERY TODAY, 2018, 48 (10) : 963 - 967
  • [30] Validating margin status in lung wedge resection for clinical stage I non-small cell lung cancer
    Noriyoshi Sawabata
    Akikazu Kawase
    Nobumasa Takahashi
    Takeshi Kawaguchi
    Tetsukan Woo
    Yuichi Saito
    Satoshi Shiono
    Noriyuki Matsutani
    Surgery Today, 2018, 48 : 963 - 967